|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.19 EUR | +1.70% |
|
-0.73% | +43.00% |
| 07-24 | Viatris Wins European Medicines Agency's Positive Opinion for Ruxolitinib Viatris | MT |
| 07-24 | Merck licenses experimental HIV pill to generic makers in 129 countries | RE |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- VTRS Stock
- 1VTRS Stock
- Consensus Viatris Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
